Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Daniel Saltzstein, MD

Articles by Daniel Saltzstein, MD

The Impact of PSMA PET Imaging on Staging and Treatment Decisions in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 1st 2025

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Assessing Comorbidities in mCSPC Management

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 1st 2025

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Mechanisms of Action and Differentiation Among ARPI Therapies in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

November 24th 2025

Mechanisms of Action and Differentiation Among ARPI Therapies in mCSPC

Current Treatment Landscape and Guideline Recommendations in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

November 24th 2025

Current Treatment Landscape and Guideline Recommendations in mCSPC

Latest Updated Articles

Trending on Urology Times

FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

© 2025 MJH Life Sciences^®

All rights reserved.